drugset / Trial / NCT01697592

Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)

NCT01697592

Phase 3 Completed 585 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will examine the safety and efficacy of the addition of omarigliptin in Japanese participants with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy and oral antihyperglycemic agent monotherapy.

Timeline

Start
2012-10-24
Primary completion
2014-05-08
Completion
2014-05-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Omarigliptin Small molecule 25 mg Oral